Section Arrow
MRNA.NASDAQ
- Moderna
Quotes are at least 15-min delayed:2026/02/11 00:51 EST
Regular Hours
Last
 41.995
+0.045 (+0.11%)
Day High 
45.5 
Prev. Close
41.95 
1-M High
55.2 
Volume 
9.99M 
Bid
38.25
Ask
38.29
Day Low
41.68 
Open
42.87 
1-M Low
32.37 
Market Cap 
16.39B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 43.3 
20-SMA 43.48 
50-SMA 35.43 
52-W High 55.2 
52-W Low 22.28 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-8.06/-4.34
Enterprise Value
17.10B
Balance Sheet
Book Value Per Share
23.88
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
3.20B
Operating Revenue Per Share
23.26
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
QNCXQuince Therapeutics0.5277+0.3977+305.92%-- 
PHIOPhio Pharmaceuticals Corp1.12+0.22+24.44%-- 
ABPAbpro Holdings Inc1.67+0.15+9.87%-- 
IBRXImmunityBio6.56-0.37-5.34%-- 
HURATuHURA Biosciences Inc1.3+0.4899+60.47%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.